Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2024.Dec.10

Announcement on behalf of OBIGEN to acquire the worldwide intellectual property rights of OBI-858 and sign the technology transfer agreement

2024.Dec.10

OBI’s BOD resolved to transfer the worldwide intellectual property rights of OBI-858 and sign the technology transfer agreement

2024.Dec.10

The Company’s BOD resolved the redemption and cancellation of the Restricted Stock Awards and the record date of capital reduction

2024.Dec.06

Announcement of the expiration of the Company's 2024 cash capital increase call period and the issuance of stocks

2024.Nov.26

Announcement on behalf of OBIGEN that it has filed the application of repeat-dose Phase II safety study for OBI-858 to TFDA

2024.Nov.15

OBI is invited to present the current development status of its products and technology platforms at the investor conference hosted by MasterLink

2024.Nov.12

Announcement of the Company's full receipt of cash capital increase in 2024 and the reference date of capital increase

2024.Nov.05

Subscription rights to the cash issue forfeited by directors of the Company reaching 50% and subscription being made available to specific persons

2024.Nov.05

Announcement of calls on unpaid shares of 2024 cash capital increase

2024.Nov.04

Announcement of the Consolidated Financial Statements for the third quarter of 2024 were approved by the Board of Directors.

News

Latest News

Events

Latest events